REVOLUTION MEDICINES INC (RVMD)

US76155X1000 - Common Stock

44.06  +0.77 (+1.78%)

After market: 43.8 -0.26 (-0.59%)

Fundamental Rating

3

RVMD gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. While RVMD has a great health rating, there are worries on its profitability. While showing a medium growth rate, RVMD is valued expensive at the moment.



1

1. Profitability

1.1 Basic Checks

RVMD had negative earnings in the past year.
In the past year RVMD has reported a negative cash flow from operations.
In the past 5 years RVMD always reported negative net income.
RVMD had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -32.16%, RVMD is in the better half of the industry, outperforming 65.49% of the companies in the same industry.
Looking at the Return On Equity, with a value of -36.20%, RVMD is in the better half of the industry, outperforming 75.40% of the companies in the same industry.
Industry RankSector Rank
ROA -32.16%
ROE -36.2%
ROIC N/A
ROA(3y)-25.72%
ROA(5y)-24.94%
ROE(3y)-30.41%
ROE(5y)-31.02%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

RVMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

8

2. Health

2.1 Basic Checks

RVMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RVMD has more shares outstanding
The number of shares outstanding for RVMD has been increased compared to 5 years ago.
RVMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 23.32 indicates that RVMD is not in any danger for bankruptcy at the moment.
RVMD's Altman-Z score of 23.32 is amongst the best of the industry. RVMD outperforms 93.98% of its industry peers.
There is no outstanding debt for RVMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.32
ROIC/WACCN/A
WACC10.91%

2.3 Liquidity

RVMD has a Current Ratio of 14.24. This indicates that RVMD is financially healthy and has no problem in meeting its short term obligations.
RVMD's Current ratio of 14.24 is amongst the best of the industry. RVMD outperforms 89.03% of its industry peers.
A Quick Ratio of 14.24 indicates that RVMD has no problem at all paying its short term obligations.
The Quick ratio of RVMD (14.24) is better than 89.03% of its industry peers.
Industry RankSector Rank
Current Ratio 14.24
Quick Ratio 14.24

4

3. Growth

3.1 Past

RVMD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.02%.
RVMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -97.16%.
The Revenue for RVMD have been decreasing by -10.50% on average. This is quite bad
EPS 1Y (TTM)-10.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.34%
Revenue 1Y (TTM)-97.16%
Revenue growth 3Y-35.41%
Revenue growth 5Y-10.5%
Sales Q2Q%N/A

3.2 Future

RVMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.29% yearly.
The Revenue is expected to grow by 123.21% on average over the next years. This is a very strong growth
EPS Next Y5.94%
EPS Next 2Y-3.31%
EPS Next 3Y-3.81%
EPS Next 5Y12.29%
Revenue Next Year-97.31%
Revenue Next 2Y-27.45%
Revenue Next 3Y19.52%
Revenue Next 5Y123.21%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

0

4. Valuation

4.1 Price/Earnings Ratio

RVMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RVMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as RVMD's earnings are expected to decrease with -3.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.31%
EPS Next 3Y-3.81%

0

5. Dividend

5.1 Amount

No dividends for RVMD!.
Industry RankSector Rank
Dividend Yield N/A

REVOLUTION MEDICINES INC

NASDAQ:RVMD (12/20/2024, 8:00:01 PM)

After market: 43.8 -0.26 (-0.59%)

44.06

+0.77 (+1.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners103.07%
Inst Owner Change1.56%
Ins Owners2.09%
Ins Owner Change0.15%
Market Cap8.12B
Analysts88.57
Price Target72.86 (65.37%)
Short Float %8.99%
Short Ratio9.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.83%
Min EPS beat(2)-3.17%
Max EPS beat(2)-2.48%
EPS beat(4)1
Avg EPS beat(4)-6.08%
Min EPS beat(4)-26.7%
Max EPS beat(4)8.02%
EPS beat(8)4
Avg EPS beat(8)0.93%
EPS beat(12)6
Avg EPS beat(12)0.32%
EPS beat(16)7
Avg EPS beat(16)-2.87%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-83.33%
Min Revenue beat(4)-100%
Max Revenue beat(4)-33.33%
Revenue beat(8)3
Avg Revenue beat(8)-8.18%
Revenue beat(12)5
Avg Revenue beat(12)-7.85%
Revenue beat(16)6
Avg Revenue beat(16)-14.67%
PT rev (1m)18.9%
PT rev (3m)19.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.93%
EPS NY rev (1m)-1.02%
EPS NY rev (3m)-0.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-79.46%
Revenue NY rev (1m)7.14%
Revenue NY rev (3m)-78.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10944.93
P/FCF N/A
P/OCF N/A
P/B 5.18
P/tB 5.43
EV/EBITDA N/A
EPS(TTM)-3.59
EYN/A
EPS(NY)-4.03
Fwd EYN/A
FCF(TTM)-2.99
FCFYN/A
OCF(TTM)-2.93
OCFYN/A
SpS0
BVpS8.5
TBVpS8.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.16%
ROE -36.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.72%
ROA(5y)-24.94%
ROE(3y)-30.41%
ROE(5y)-31.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 157.62%
Cap/Sales 1537.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.24
Quick Ratio 14.24
Altman-Z 23.32
F-Score4
WACC10.91%
ROIC/WACCN/A
Cap/Depr(3y)166.18%
Cap/Depr(5y)131.14%
Cap/Sales(3y)39.85%
Cap/Sales(5y)26.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.34%
EPS Next Y5.94%
EPS Next 2Y-3.31%
EPS Next 3Y-3.81%
EPS Next 5Y12.29%
Revenue 1Y (TTM)-97.16%
Revenue growth 3Y-35.41%
Revenue growth 5Y-10.5%
Sales Q2Q%N/A
Revenue Next Year-97.31%
Revenue Next 2Y-27.45%
Revenue Next 3Y19.52%
Revenue Next 5Y123.21%
EBIT growth 1Y-77.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-52.24%
EBIT Next 3Y-21.74%
EBIT Next 5Y-2.34%
FCF growth 1Y-161.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-167.35%
OCF growth 3YN/A
OCF growth 5YN/A